West Pharmaceutical Services (WST) Cash from Financing Activities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Cash from Financing Activities for 18 consecutive years, with -$164.8 million the latest figure, recorded in Q2 2026.

• Quarterly Cash from Financing Activities fell 1006.04% year-over-year to -$164.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$496.7 million (down 68.26% YoY) and the FY2025 annual result came in at -$185.1 million, up 70.27% from the prior year.
• Cash from Financing Activities climbed to -$164.8 million in Q2 2026 per WST's latest filing, from -$308.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for WST reached as high as -$9.5 million in Q4 2022 and fell as low as -$308.7 million in Q1 2026.
• A 5-year average of -$113.0 million and a median of -$73.1 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 12166.67% — and 2025, when it jumped 93.17%.
• Year by year, Cash from Financing Activities stood at -$9.5 million in 2022, then tumbled by 1894.74% to -$189.5 million in 2023, then jumped by 63.64% to -$68.9 million in 2024, then soared by 83.02% to -$11.7 million in 2025, then plunged by 1308.55% to -$164.8 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$164.8 million, -$308.7 million, and -$11.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.